{
  "id": "CD012532.PUB2",
  "draft": "\"Do immune checkpoint drugs (anti‑PD‑1 and anti‑PD‑L1 antibodies) help people with aggressive brain tumors (glioma) live longer?\"\n\nKey messages\n- Medicines that block PD‑1 or PD‑L1 do not appear to extend survival for people with glioblastoma, the most aggressive brain tumour, and they may increase serious side‑effects. The evidence comes from a small number of low‑quality studies, so confidence is low.\n- A very small trial that gave pembrolizumab (a PD‑1 blocker) before and after tumour removal suggested a possible survival benefit, but the study was tiny and the result is uncertain, so it cannot be relied upon.\n- Larger, high‑quality randomised trials are needed to determine whether any groups of patients might benefit from these drugs and to assess both benefits and harms over longer follow‑up.\n\nWhat do we need to know about glioblastoma?\nGlioblastoma multiforme (GBM) is the most common and fast‑growing brain tumour in adults. It spreads quickly through the brain and is hard to remove completely with surgery. Because of its aggressiveness, the median survival after diagnosis is about 16 months – half of patients live longer and half live shorter. Symptoms often include headaches, seizures, and loss of thinking or movement abilities.\n\nWhy might new drugs be needed?\nStandard treatment combines maximal safe surgery, radiotherapy (high‑energy X‑rays that kill cancer cells) and the chemotherapy pill temozolomide. Some patients also receive bevacizumab, a drug that blocks new blood‑vessel growth. Even with these therapies, most patients survive only a short time, so researchers are looking for new options. Immune checkpoint inhibitors are medicines that block proteins called PD‑1 on immune cells and PD‑L1 on tumour cells. These proteins normally keep the immune system from attacking the tumour. By blocking them, the drugs aim to “release the brakes” on the immune system. However, GBM creates an environment that suppresses immune activity, which may limit the drugs’ effectiveness.\n\nHow did we find the evidence?\nWe searched the Cochrane Central Register of Controlled Trials, MEDLINE, Embase and trial registers up to March 2024 for randomised controlled trials that compared anti‑PD‑1 or anti‑PD‑L1 antibodies with placebo or other standard treatments in adults with diffuse glioma. We extracted data on overall survival (how long people lived), progression‑free survival (time until the tumour grew or symptoms worsened), serious adverse events (health problems that required hospitalisation or were life‑threatening), tumour response, and quality of life. We assessed the certainty of the evidence using standard Cochrane methods.\n\nWhat did we find?\nWe identified seven trials involving 1 953 participants with grade 4 glioma (glioblastoma). Four trials enrolled people with recurrent disease and three enrolled newly diagnosed patients. All trials tested anti‑PD‑1 antibodies – mainly nivolumab or pembrolizumab – either alone or together with bevacizumab, radiotherapy or temozolomide. No anti‑PD‑L1 – no trials of PD‑L1 blockers – were found.\n\nAcross the studies, anti‑PD‑1 therapy probably does not improve overall survival or progression‑free survival in glioblastoma, whether the disease is recurrent or newly diagnosed. Specific findings include:\n- Nivolumab showed little or no benefit compared with bevacizumab in recurrent GBM.\n- Higher‑dose bevacizumab combined with nivolumab did not improve survival.\n- Adding bevacizumab to pembrolizumab, or giving pembrolizumab around surgery, gave unclear results.\n- In newly diagnosed patients, nivolumab combined with radiotherapy (with or without temozolomide) made little or no difference to survival outcomes. The combination with temozolomide increased serious adverse events in tumours with a methylated MGMT promoter.\n- Nivolumab plus temozolomide showed little or no effect on survival in older patients.\n\nOverall, anti‑PD‑1 antibodies appear to have little impact on how long people with glioblastoma live or on tumour progression, and they may raise the risk of serious side‑effects.\n\nWhat are the limitations of the evidence?\nWe have moderate confidence in these conclusions because many trials were small, some participants may have known which treatment they received (risk of bias), and the studies varied in patient characteristics and treatment delivery. The limited number of trials prevents firm conclusions, especially for sub‑groups.\n\nHow up‑to‑date is the evidence?\nWe searched the literature up to March 2024, so the summary reflects all relevant randomised evidence available at that time.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 700,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 34,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 20.58823529411765,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 16,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 70,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 31,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 16,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 203,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 203.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 45.743655462184876,
          "rating": "P50",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 11.9936974789916,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 12.414117647058823,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 12.162285714285712,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 17.321008403361343,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 51.73109243697479,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 6.411764705882353,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 15.041594578792296,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 15.0 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 8.17179075630252,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 8.2 to <7.7 (median)"
        },
        "complex_words_dc": {
          "value": 317,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 317.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 159,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 159.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 218,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 218.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 700,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 700 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 0,
        "P50_count": 8,
        "P75_count": 4,
        "P90_count": 1,
        "P10_count": 0,
        "BEYOND_P90_count": 5,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 0,
        "P50_percentage": 44.44444444444444,
        "P75_percentage": 22.22222222222222,
        "P90_percentage": 5.555555555555555,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 27.77777777777778,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 22.22222222222222,
        "overall_assessment": "MODERATE CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The draft is missing clear explanations for a few key technical terms (e.g., “MGMT promoter” and “immune checkpoint inhibitors”), contains several long noun‑heavy sentences that are hard for patients to follow, and includes sentences that exceed 30 words, reducing readability. These issues create potential confusion for a lay audience and are reflected in the metric deviations (high noun count, high SMOG and Dale‑Chall scores). The draft also exceeds typical PLS patterns for complex and long words, which further hampers comprehension. To meet Cochrane plain‑language standards, the text needs simpler wording, shorter sentences, and brief definitions of specialised terms.",
      "pls_evaluation_summary": "The PLS evaluation shows the draft is within the 850‑word limit but deviates markedly from typical PLS patterns: noun count (203) is beyond the P90 range, SMOG index (15.0) and Dale‑Chall readability (8.17) are higher than typical, and the numbers of complex, long, and Dale‑Chall unfamiliar words are all well above median values. These metrics confirm the need to reduce noun density, simplify vocabulary, and shorten sentences."
    }
  ]
}